PT817847E - Receptor de il-17 - Google Patents
Receptor de il-17Info
- Publication number
- PT817847E PT817847E PT96912451T PT96912451T PT817847E PT 817847 E PT817847 E PT 817847E PT 96912451 T PT96912451 T PT 96912451T PT 96912451 T PT96912451 T PT 96912451T PT 817847 E PT817847 E PT 817847E
- Authority
- PT
- Portugal
- Prior art keywords
- receptors
- receptor
- isolated
- ctla
- inhibit
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
- C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Toxicology (AREA)
- Biomedical Technology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cell Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Transplantation (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US41053595A | 1995-03-23 | 1995-03-23 | |
US53876595A | 1995-08-07 | 1995-08-07 |
Publications (1)
Publication Number | Publication Date |
---|---|
PT817847E true PT817847E (pt) | 2005-02-28 |
Family
ID=27021039
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PT96912451T PT817847E (pt) | 1995-03-23 | 1996-03-21 | Receptor de il-17 |
Country Status (15)
Country | Link |
---|---|
US (9) | US5869286A (pt) |
EP (1) | EP0817847B2 (pt) |
JP (1) | JP4373495B2 (pt) |
KR (1) | KR100467998B1 (pt) |
AT (1) | ATE279517T1 (pt) |
AU (1) | AU696775B2 (pt) |
CA (1) | CA2215394C (pt) |
DE (1) | DE69633617T3 (pt) |
DK (1) | DK0817847T4 (pt) |
ES (1) | ES2229264T5 (pt) |
MX (1) | MX9707021A (pt) |
NO (1) | NO974258L (pt) |
NZ (1) | NZ306653A (pt) |
PT (1) | PT817847E (pt) |
WO (1) | WO1996029408A1 (pt) |
Families Citing this family (89)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6274711B1 (en) * | 1993-06-14 | 2001-08-14 | Inserm, Institut National De La Sante Et De La Recherche Medicale | Purified mammalian CTLA-8 antigens and related reagents |
US5869286A (en) * | 1995-03-23 | 1999-02-09 | Immunex Corporation | Receptor that binds IL-17 |
US6680057B1 (en) * | 1995-03-23 | 2004-01-20 | Immunex Corporation | Methods of treating autoimmune disease by administering interleukin-17 receptor |
US6902735B1 (en) | 1995-07-19 | 2005-06-07 | Genetics Institute, Llc | Antibodies to human IL-17F and other CTLA-8-related proteins |
AU727480B2 (en) * | 1995-07-19 | 2000-12-14 | Genetics Institute, Llc | Human CTLA-8 and uses of CTLA-8-related proteins |
US6074849A (en) * | 1995-07-19 | 2000-06-13 | Genetics Institute, Inc. | Polynucleotides encoding human CTLA-8 related proteins |
US7005412B1 (en) * | 1996-11-27 | 2006-02-28 | Immunex Corporation | Method of treating ulcerative colitis and Crohn's disease using IL-17 receptor proteins |
ES2326347T3 (es) * | 1996-11-27 | 2009-10-07 | Immunex Corporation | Metodo para regular la produccion de oxido nitrico. |
US6579520B2 (en) * | 1998-05-15 | 2003-06-17 | Genentech, Inc. | IL-17 related mammalian cytokine polypeptides (IL-17E) |
ES2333385T3 (es) | 1997-09-17 | 2010-02-19 | Human Genome Sciences, Inc. | Proteina del tipo de interleuquina-17. |
US6482923B1 (en) * | 1997-09-17 | 2002-11-19 | Human Genome Sciences, Inc. | Interleukin 17-like receptor protein |
US6849719B2 (en) | 1997-09-17 | 2005-02-01 | Human Genome Sciences, Inc. | Antibody to an IL-17 receptor like protein |
WO1999032659A1 (en) * | 1997-12-22 | 1999-07-01 | Stiftelsen Universitetsforskning Bergen (Unifob) | METHOD FOR DISEASE PROGNOSIS BASED ON Fc RECEPTOR GENOTYPING |
EP1045905A2 (en) * | 1998-01-09 | 2000-10-25 | Immunex Corporation | Il-17rh dna and polypeptides |
US7771719B1 (en) * | 2000-01-11 | 2010-08-10 | Genentech, Inc. | Pharmaceutical compositions, kits, and therapeutic uses of antagonist antibodies to IL-17E |
DK1076703T4 (da) | 1998-05-15 | 2011-03-28 | Genentech Inc | Terapeutiske anvendelser af IL-17-homologe polypeptider |
US20050147609A1 (en) * | 1998-05-15 | 2005-07-07 | Genentech, Inc. | Use of anti-IL-17 antibody for the treatment of cartilage damaged by osteoarthritis |
US8133734B2 (en) | 1999-03-16 | 2012-03-13 | Human Genome Sciences, Inc. | Kit comprising an antibody to interleukin 17 receptor-like protein |
JP2002541195A (ja) * | 1999-04-14 | 2002-12-03 | アメリカ合衆国 | 移植片に対する免疫寛容を誘導するための、免疫毒素および樹状細胞の成熟を阻害する作用剤を含有する組成物 |
WO2000064327A2 (en) * | 1999-04-26 | 2000-11-02 | Duke University | Inhibition of complement action |
US6936424B1 (en) * | 1999-11-16 | 2005-08-30 | Matritech, Inc. | Materials and methods for detection and treatment of breast cancer |
PT1897945E (pt) * | 1999-12-23 | 2012-03-29 | Genentech Inc | Polipéptidos homólogos de il-17 e suas utilizações terapêuticas |
EP1897947B1 (en) * | 1999-12-23 | 2012-01-18 | Genentech, Inc. | IL-17 homologous polypeptides and therapeutic uses thereof |
JP2016047051A (ja) * | 1999-12-23 | 2016-04-07 | ジェネンテック, インコーポレイテッド | Il−17相同的ポリペプチドとその治療上の用途 |
US20040043397A1 (en) | 2000-01-11 | 2004-03-04 | Genentech, Inc. | IL-17 homologous polypeptides and therapeutic uses thereof |
MXPA02009055A (es) * | 2000-03-16 | 2003-03-12 | Amgen Inc | Receptor il-17 como moleculas y usos de los mismos. |
US7718397B2 (en) | 2000-03-21 | 2010-05-18 | Genentech, Inc. | Nucleic acids encoding receptor for IL-17 homologous polypeptides and uses thereof |
US20030092881A1 (en) * | 2000-05-24 | 2003-05-15 | Gorman Daniel M. | Mammalian receptor proteins; related reagents and methods |
DK2990420T3 (en) | 2000-05-26 | 2017-04-03 | Immunex Corp | USE OF INTERLEUKIN-4 RECEPTOR ANTIBODIES AND COMPOSITIONS THEREOF |
US20030096969A1 (en) | 2000-06-02 | 2003-05-22 | Genentech, Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
WO2002004519A2 (en) * | 2000-07-06 | 2002-01-17 | Zymogenetics, Inc. | Murine cytokine receptor |
WO2002008259A2 (en) * | 2000-07-26 | 2002-01-31 | Zymogenetics, Inc. | Human cytokine receptor |
MXPA03003407A (es) * | 2000-10-18 | 2004-05-04 | Immunex Corp | Metodos para el tratamiento de artritis reumatoide usando antagonistas il-17. |
WO2002038764A2 (en) * | 2000-11-10 | 2002-05-16 | The Regents Of The University Of California | Il-17 receptor-like protein, uses thereof, and modulation of catabolic activity of il-17 cytokines on bone and cartilage |
US20040136992A1 (en) | 2002-08-28 | 2004-07-15 | Burton Paul B. J. | Compositions and method for treating cardiovascular disease |
EP2322203A3 (en) * | 2002-10-29 | 2011-07-27 | Genentech, Inc. | Compositions and methods for the treatment of immune related diseases |
JP4441170B2 (ja) * | 2002-11-28 | 2010-03-31 | 独立行政法人理化学研究所 | S12リボソームタンパク質に変異を有する大腸菌細胞抽出液及びそれを用いる無細胞系によるタンパク質の製造方法 |
EP2135952A3 (en) * | 2003-09-15 | 2010-09-29 | Research Development Foundation | Cripto antagonism of activin and TGF-beta signaling |
JP2008501035A (ja) * | 2004-05-28 | 2008-01-17 | アプライド リサーチ システムズ エーアールエス ホールディング ナームロゼ フェンノートシャップ | 妊孕性関連障害の治療におけるil−17の使用 |
EP1765865A2 (en) | 2004-06-10 | 2007-03-28 | ZymoGenetics, Inc. | Soluble zcytor14, anti-zcytor14 antibodies and binding partners and methods of using in inflammation |
GB0417487D0 (en) | 2004-08-05 | 2004-09-08 | Novartis Ag | Organic compound |
EP1794593A2 (en) * | 2004-09-21 | 2007-06-13 | Matritech, Inc. | Methods and compositions for detecting cancer using components of the u2 spliceosomal particle |
JP2008516985A (ja) * | 2004-10-18 | 2008-05-22 | ザイモジェネティクス,インコーポレイティド | 可溶性zcytor21、抗zcytor21抗体及び結合パートナー、並びに炎症における使用方法 |
JP4590249B2 (ja) * | 2004-11-17 | 2010-12-01 | 独立行政法人理化学研究所 | 糖タンパク質合成用の無細胞タンパク質合成システム |
JP4868731B2 (ja) | 2004-11-17 | 2012-02-01 | 独立行政法人理化学研究所 | 哺乳動物培養細胞由来の無細胞タンパク質合成システム |
JP4787488B2 (ja) * | 2004-11-19 | 2011-10-05 | 独立行政法人理化学研究所 | 直鎖状鋳型dnaを用いた無細胞タンパク質合成方法及びそのための細胞抽出液 |
EP1848743A2 (en) * | 2005-02-14 | 2007-10-31 | Wyeth | Interleukin-17f antibodies and other il-17f signaling antagonists and uses therefor |
EP1849011A2 (en) * | 2005-02-14 | 2007-10-31 | University of Pittsburgh of the Commonwealth System of Higher Education | Use of il-17f in diagnosis and therapy of airway inflammation |
GB0504436D0 (en) * | 2005-03-03 | 2005-04-06 | Glaxosmithkline Biolog Sa | Vaccine |
SG162788A1 (en) | 2005-06-14 | 2010-07-29 | Amgen Inc | Self-buffering protein formulations |
EP1933869B1 (en) | 2005-09-01 | 2009-10-14 | Schering Corporation | Use of il-23 and il-17 antagonists to treat autoimmune ocular inflammatory disease |
US20070249533A1 (en) | 2005-09-28 | 2007-10-25 | Levin Steven D | Il-17a and il-17f antagonists and methods of using the same |
ES2347840T3 (es) | 2006-02-10 | 2010-11-04 | Zymogenetics, Inc. | Il-17rcx4 soluble y procedimiento de utilizacion en la inflamacion. |
EP1996616A1 (en) * | 2006-02-10 | 2008-12-03 | Zymogenetics, Inc. | Truncated il-17ra soluble receptor and methods of using in inflammation |
WO2007149814A1 (en) * | 2006-06-19 | 2007-12-27 | Wyeth | Methods of modulating il-22 and il-17 |
US7767206B2 (en) | 2006-10-02 | 2010-08-03 | Amgen Inc. | Neutralizing determinants of IL-17 Receptor A and antibodies that bind thereto |
FR2908999B1 (fr) * | 2006-11-29 | 2012-04-27 | Biomerieux Sa | Nouveau medicament destine a l'inhibition, la prevention ou le traitement de la polyarthrite rhumatoide. |
FR2910324B1 (fr) * | 2006-12-21 | 2009-03-06 | Biomerieux Sa | Nouveau medicament pour le traitement d'un cancer gastrique |
EP2417974A1 (en) | 2007-02-28 | 2012-02-15 | Schering Corporation | Combination therapy for treatment of immune disorders |
MX2009010273A (es) | 2007-03-26 | 2009-10-12 | Zymogenetics Inc | Proteinas de fusion il-17ra/rc solubles y metodos relacionados. |
CL2008000883A1 (es) * | 2007-03-28 | 2008-10-03 | Wyeth6 3 | Metodo de deteccion de compuestos capaces de antagonizar la senalizacion de il-17f/il-17a; compuesto identificado por dicho metodo; uso de una cantidad de un antagonista de senalizacion de il-17f/il-17a, composicion farmaceutica que comprende dicho a |
EP2144928A2 (en) * | 2007-04-20 | 2010-01-20 | Amgen Inc. | Jacquelinidentification and method for using the pre-ligand assembly domain of the il-17 receptor |
WO2009015063A2 (en) * | 2007-07-23 | 2009-01-29 | Centocor | Methods and compositions for treating fibrosis related disorders using il-17 antagonists |
WO2009042162A2 (en) * | 2007-09-25 | 2009-04-02 | Genzyme Corporation | Compositions and methods for inhibiting interleukin pathways |
JP5704677B2 (ja) * | 2007-11-05 | 2015-04-22 | 独立行政法人理化学研究所 | 膜タンパク質の製造方法 |
CN102037017B (zh) * | 2008-02-21 | 2014-07-09 | 麒麟-安姆根有限公司 | Il-17ra-il-17rb拮抗物及其用途 |
US20090317400A1 (en) | 2008-05-05 | 2009-12-24 | Krzysztof Masternak | Anti-IL 17A/IL-17F Cross-Reactive Antibodies and Methods of Use Thereof |
EP2166358A1 (en) * | 2008-09-17 | 2010-03-24 | Fundacio Institut de Recerca de l'Hospital Universitari Vall d'Hebron | Differential diagnostic biomarkers of stroke mimicking conditions and methods of use thereof |
US20100233270A1 (en) | 2009-01-08 | 2010-09-16 | Northwestern University | Delivery of Oligonucleotide-Functionalized Nanoparticles |
EP3385279B1 (en) | 2009-03-20 | 2020-02-26 | Amgen Inc. | Carrier immunoglobulins and uses thereof |
PE20120815A1 (es) | 2009-05-05 | 2012-07-08 | Novimmune Sa | Anticuerpos anti il-17f y metodos de uso de los mismos |
KR20120093932A (ko) * | 2009-10-10 | 2012-08-23 | 일레븐 바이오테라피틱스, 아이엔씨. | Il-17 패밀리 사이토카인 조성물들 및 용도들 |
TW201117824A (en) | 2009-10-12 | 2011-06-01 | Amgen Inc | Use of IL-17 receptor a antigen binding proteins |
CN102821787B (zh) | 2010-01-15 | 2015-07-29 | 麒麟-安姆根有限公司 | 抗体制剂和治疗方案 |
JP6159660B2 (ja) | 2010-09-22 | 2017-07-05 | アムジエン・インコーポレーテツド | 担体としての免疫グロブリンおよびその使用 |
CA2833748C (en) | 2011-04-20 | 2019-07-16 | Amgen Inc. | Autoinjector apparatus |
WO2013016220A1 (en) | 2011-07-22 | 2013-01-31 | Amgen Inc. | Il-17 receptor a is required for il-17c biology |
US9284283B2 (en) | 2012-02-02 | 2016-03-15 | Ensemble Therapeutics Corporation | Macrocyclic compounds for modulating IL-17 |
JP6336564B2 (ja) | 2013-03-15 | 2018-06-06 | アムゲン・インコーポレーテッド | 薬物カセット、自動注入器、および自動注入器システム |
TWI580452B (zh) | 2013-03-15 | 2017-05-01 | 安美基公司 | 用於注射器之匣盒、注射器及使用包括自動注射器及匣盒之設備之方法 |
WO2015153144A1 (en) | 2014-03-31 | 2015-10-08 | Kirin-Amgen, Inc. | Methods of treating nail and scalp psoriasis |
CA3032514C (en) | 2015-07-31 | 2021-05-04 | Takehiro SHINODA | Method of producing membrane protein and utilization thereof |
AU2017261360A1 (en) | 2016-05-06 | 2018-11-29 | Exicure Operating Company | Liposomal Spherical Nucleic Acid (SNA) constructs presenting Antisense Oligonucleotides (ASO) for specific knockdown of interleukin 17 receptor MRNA |
WO2018018082A1 (en) | 2016-07-26 | 2018-02-01 | The Australian National University | Immunostimulatory compositions and uses therefor |
WO2018201090A1 (en) | 2017-04-28 | 2018-11-01 | Exicure, Inc. | Synthesis of spherical nucleic acids using lipophilic moieties |
EP3710089A1 (en) | 2017-11-16 | 2020-09-23 | Amgen Inc. | Autoinjector with stall and end point detection |
CN114107385A (zh) | 2019-01-17 | 2022-03-01 | 百奥赛图(北京)医药科技股份有限公司 | 人源化转基因动物 |
CA3150951A1 (en) | 2019-09-11 | 2021-03-18 | Bausch Health Ireland Limited | Methods of treating nonalcoholic fatty liver disease (nafld) using il-17ra antibody |
JP2022176672A (ja) * | 2021-05-17 | 2022-11-30 | 国立大学法人北海道大学 | ペプチド及び医薬用組成物 |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5116964A (en) * | 1989-02-23 | 1992-05-26 | Genentech, Inc. | Hybrid immunoglobulins |
US5703088A (en) * | 1989-08-21 | 1997-12-30 | Beth Israel Deaconess Medical Center, Inc. | Topical application of spiperone or derivatives thereof for treatment of pathological conditions associated with immune responses |
US5716805A (en) * | 1991-10-25 | 1998-02-10 | Immunex Corporation | Methods of preparing soluble, oligomeric proteins |
US6274711B1 (en) * | 1993-06-14 | 2001-08-14 | Inserm, Institut National De La Sante Et De La Recherche Medicale | Purified mammalian CTLA-8 antigens and related reagents |
US6562333B1 (en) * | 1993-06-14 | 2003-05-13 | Schering Corporation | Purified mammalian CTLA-8 antigens and related reagents |
US5869286A (en) * | 1995-03-23 | 1999-02-09 | Immunex Corporation | Receptor that binds IL-17 |
US6074849A (en) * | 1995-07-19 | 2000-06-13 | Genetics Institute, Inc. | Polynucleotides encoding human CTLA-8 related proteins |
ES2326347T3 (es) * | 1996-11-27 | 2009-10-07 | Immunex Corporation | Metodo para regular la produccion de oxido nitrico. |
MXPA03003407A (es) * | 2000-10-18 | 2004-05-04 | Immunex Corp | Metodos para el tratamiento de artritis reumatoide usando antagonistas il-17. |
-
1996
- 1996-03-21 US US08/620,694 patent/US5869286A/en not_active Expired - Lifetime
- 1996-03-21 EP EP96912451A patent/EP0817847B2/en not_active Expired - Lifetime
- 1996-03-21 WO PCT/US1996/004018 patent/WO1996029408A1/en active IP Right Grant
- 1996-03-21 JP JP52865596A patent/JP4373495B2/ja not_active Expired - Lifetime
- 1996-03-21 CA CA2215394A patent/CA2215394C/en not_active Expired - Lifetime
- 1996-03-21 AU AU55263/96A patent/AU696775B2/en not_active Expired
- 1996-03-21 MX MX9707021A patent/MX9707021A/es unknown
- 1996-03-21 KR KR1019970706470A patent/KR100467998B1/ko not_active IP Right Cessation
- 1996-03-21 NZ NZ306653A patent/NZ306653A/xx not_active IP Right Cessation
- 1996-03-21 AT AT96912451T patent/ATE279517T1/de active
- 1996-03-21 ES ES96912451T patent/ES2229264T5/es not_active Expired - Lifetime
- 1996-03-21 DE DE69633617T patent/DE69633617T3/de not_active Expired - Lifetime
- 1996-03-21 PT PT96912451T patent/PT817847E/pt unknown
- 1996-03-21 DK DK96912451T patent/DK0817847T4/da active
-
1997
- 1997-09-15 NO NO974258A patent/NO974258L/no unknown
-
1998
- 1998-02-11 US US09/022,257 patent/US6197525B1/en not_active Expired - Lifetime
- 1998-02-11 US US09/022,253 patent/US6096305A/en not_active Expired - Lifetime
- 1998-02-11 US US09/022,260 patent/US6100235A/en not_active Expired - Lifetime
- 1998-02-11 US US09/022,255 patent/US6072033A/en not_active Expired - Lifetime
- 1998-02-11 US US09/022,259 patent/US6191104B1/en not_active Expired - Lifetime
- 1998-02-12 US US09/022,696 patent/US6072037A/en not_active Expired - Lifetime
-
2007
- 2007-09-19 US US11/901,904 patent/US20090068737A1/en not_active Abandoned
-
2010
- 2010-03-11 US US12/722,477 patent/US20100233186A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
US6191104B1 (en) | 2001-02-20 |
US6197525B1 (en) | 2001-03-06 |
DK0817847T3 (da) | 2005-02-14 |
NO974258L (no) | 1997-11-24 |
NO974258D0 (no) | 1997-09-15 |
US6072033A (en) | 2000-06-06 |
ES2229264T5 (es) | 2009-12-17 |
KR19980703061A (ko) | 1998-09-05 |
CA2215394C (en) | 2011-04-26 |
US6100235A (en) | 2000-08-08 |
US20100233186A1 (en) | 2010-09-16 |
ES2229264T3 (es) | 2005-04-16 |
EP0817847A1 (en) | 1998-01-14 |
WO1996029408A1 (en) | 1996-09-26 |
ATE279517T1 (de) | 2004-10-15 |
AU696775B2 (en) | 1998-09-17 |
NZ306653A (en) | 1999-03-29 |
AU5526396A (en) | 1996-10-08 |
EP0817847B2 (en) | 2009-09-09 |
DE69633617T2 (de) | 2005-11-03 |
US5869286A (en) | 1999-02-09 |
JPH11503309A (ja) | 1999-03-26 |
DE69633617D1 (de) | 2004-11-18 |
US6096305A (en) | 2000-08-01 |
JP4373495B2 (ja) | 2009-11-25 |
DK0817847T4 (da) | 2009-10-05 |
US6072037A (en) | 2000-06-06 |
US20090068737A1 (en) | 2009-03-12 |
DE69633617T3 (de) | 2010-05-20 |
KR100467998B1 (ko) | 2005-11-25 |
MX9707021A (es) | 1997-11-29 |
CA2215394A1 (en) | 1996-09-26 |
EP0817847B1 (en) | 2004-10-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PT817847E (pt) | Receptor de il-17 | |
LU91758I9 (pt) | ||
ATE360032T1 (de) | Cystein-reiche rezeptoren-train | |
FI972945A (fi) | Antigeenien antamiseen soveltuvia koostumuksia | |
DK0747050T4 (da) | Farmaceutiske sammensætninger, der indeholder irbesartan | |
EP0837927A4 (en) | MONOCLONAL MONKEY ANTIBODIES AGAINST HUMANE B7.1 AND / OR B7.2 ANTIGEN, PRIMATIZED DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS | |
IS4565A (is) | 2-methýl-thíenó-bensódíasepín, samsetning til inntöku | |
MX9206423A (es) | Composicion de perfume. | |
NO20004345D0 (no) | Farmasøytisk sammensetning | |
ITRM920476A0 (it) | Formulazioni galeniche contenenti ciclosporina. | |
DZ1559A1 (fr) | Compositions pharmaceutiques. | |
DE69600598T2 (de) | Brennstoffzusammensetzungen | |
ES1034944Y (es) | "distribuidor de tabletas." | |
DE69526738T2 (de) | Endothelin-rezeptor-antagonisten | |
DE69614552T2 (de) | MODIFIZIERTE ALPHA-D-GLCP-(1,2)-ALPHA-D-Glcp-(1,3)-ALPHA-D-Glcp-ANALOGE | |
FR2708855B1 (fr) | Compositions pharmaceutiques immunoadjuvantes ou immunostimulantes. | |
IT1294932B1 (it) | Uso di 2-amminotetraline-6,7 sostituite per la preparazione di composizioni farmaceutiche atte al trattamento di patologie | |
DE69200508D1 (de) | Modifiziertes Aethylen-alpha-olefin-nichtkonjugiertes Dien Copolymer Elastomer Zusammensetzung. | |
MY106292A (en) | (alpha)-adrenergic receptor antagonists. | |
ZA981275B (en) | Disubstituted bicyclic heterocycles, the preparation and the use thereof as pharmaceutical compositions. | |
MX9206975A (es) | Composicion farmaceutica. | |
ITMI910600A1 (it) | 6, 9-bis (amino sostituiti) benzo(g) ftalazin-5, 10-dioni come farmaci antitumorali. | |
TR199500776A2 (tr) | Farmasötik bilesimler. | |
IT8919844A0 (it) | Composizioni farmaceutiche. | |
IT239038Y1 (it) | Dispositivo per calzature, utilizzabile in particolare per prevenirela formazione di cariche elettrostatiche |